Millennium Pharmacon International (SDPC) - Net Assets
Based on the latest financial reports, Millennium Pharmacon International (SDPC) has net assets worth Rp300.33 Billion IDR (≈ $17.60 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp1.90 Trillion ≈ $111.55 Million USD) and total liabilities (Rp1.60 Trillion ≈ $93.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Millennium Pharmacon International liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp300.33 Billion |
| % of Total Assets | 15.78% |
| Annual Growth Rate | 9.72% |
| 5-Year Change | 23.26% |
| 10-Year Change | 110.32% |
| Growth Volatility | 21.35 |
Millennium Pharmacon International - Net Assets Trend (2000–2024)
This chart illustrates how Millennium Pharmacon International's net assets have evolved over time, based on quarterly financial data. Also explore SDPC current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Millennium Pharmacon International (2000–2024)
The table below shows the annual net assets of Millennium Pharmacon International from 2000 to 2024. For live valuation and market cap data, see Millennium Pharmacon International market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp282.50 Billion ≈ $16.55 Million |
+1.72% |
| 2023-12-31 | Rp277.71 Billion ≈ $16.27 Million |
+7.26% |
| 2022-12-31 | Rp258.91 Billion ≈ $15.17 Million |
+9.25% |
| 2021-12-31 | Rp236.98 Billion ≈ $13.89 Million |
+3.40% |
| 2020-12-31 | Rp229.20 Billion ≈ $13.43 Million |
-2.65% |
| 2019-12-31 | Rp235.44 Billion ≈ $13.80 Million |
+1.43% |
| 2018-12-31 | Rp232.11 Billion ≈ $13.60 Million |
+9.17% |
| 2017-12-31 | Rp212.61 Billion ≈ $12.46 Million |
+48.39% |
| 2016-12-31 | Rp143.28 Billion ≈ $8.40 Million |
+6.67% |
| 2015-12-31 | Rp134.31 Billion ≈ $7.87 Million |
+10.28% |
| 2014-12-31 | Rp121.79 Billion ≈ $7.14 Million |
+6.02% |
| 2013-12-31 | Rp114.87 Billion ≈ $6.73 Million |
+9.79% |
| 2012-12-31 | Rp104.62 Billion ≈ $6.13 Million |
+10.39% |
| 2011-12-31 | Rp94.78 Billion ≈ $5.55 Million |
+4.41% |
| 2010-12-31 | Rp90.78 Billion ≈ $5.32 Million |
+1.69% |
| 2009-12-31 | Rp89.27 Billion ≈ $5.23 Million |
+11.93% |
| 2008-12-31 | Rp79.76 Billion ≈ $4.67 Million |
+13.55% |
| 2007-12-31 | Rp70.24 Billion ≈ $4.12 Million |
+15.85% |
| 2006-12-31 | Rp60.63 Billion ≈ $3.55 Million |
+16.13% |
| 2005-12-31 | Rp52.21 Billion ≈ $3.06 Million |
+15.56% |
| 2004-12-31 | Rp45.18 Billion ≈ $2.65 Million |
+9.37% |
| 2003-12-31 | Rp41.31 Billion ≈ $2.42 Million |
+12.71% |
| 2002-12-31 | Rp36.65 Billion ≈ $2.15 Million |
+91.73% |
| 2001-12-31 | Rp19.11 Billion ≈ $1.12 Million |
-37.27% |
| 2000-12-31 | Rp30.47 Billion ≈ $1.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Millennium Pharmacon International's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16138249700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp161.38 Billion | 57.12% |
| Common Stock | Rp127.40 Billion | 45.09% |
| Other Comprehensive Income | Rp-8.58 Billion | -3.04% |
| Other Components | Rp2.31 Billion | 0.82% |
| Total Equity | Rp282.52 Billion | 100.00% |
Millennium Pharmacon International Competitors by Market Cap
The table below lists competitors of Millennium Pharmacon International ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Les Hôtels de Paris SA
PA:HDP
|
$14.11 Million |
|
RECYCLICO BATTERY METALS
F:ID4
|
$14.11 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
$14.11 Million |
|
Sequoia Econ Infrastructure
LSE:SEQI
|
$14.12 Million |
|
Euromedis Groupe SA
PA:ALEMG
|
$14.10 Million |
|
Turbo Mech Bhd
KLSE:5167
|
$14.10 Million |
|
Bodycote PLC
LSE:BOY
|
$14.10 Million |
|
Iconic Minerals Ltd
V:ICM
|
$14.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Millennium Pharmacon International's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 277,717,214,244 to 282,515,494,000, a change of 4,798,279,756 (1.7%).
- Net income of 16,914,132,000 contributed positively to equity growth.
- Dividend payments of 3,185,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 5,232,760,171.
- Other factors decreased equity by 3,698,092,073.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp16.91 Billion | +5.99% |
| Dividends Paid | Rp3.19 Billion | -1.13% |
| Other Comprehensive Income | Rp-5.23 Billion | -1.85% |
| Other Changes | Rp-3.70 Billion | -1.31% |
| Total Change | Rp- | 1.73% |
Book Value vs Market Value Analysis
This analysis compares Millennium Pharmacon International's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.57x to 0.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | Rp120.34 | Rp189.00 | x |
| 2010-12-31 | Rp122.37 | Rp189.00 | x |
| 2011-12-31 | Rp127.76 | Rp189.00 | x |
| 2012-12-31 | Rp141.04 | Rp189.00 | x |
| 2013-12-31 | Rp154.85 | Rp189.00 | x |
| 2014-12-31 | Rp164.18 | Rp189.00 | x |
| 2015-12-31 | Rp181.06 | Rp189.00 | x |
| 2016-12-31 | Rp193.14 | Rp189.00 | x |
| 2017-12-31 | Rp283.20 | Rp189.00 | x |
| 2018-12-31 | Rp182.19 | Rp189.00 | x |
| 2019-12-31 | Rp184.80 | Rp189.00 | x |
| 2020-12-31 | Rp179.90 | Rp189.00 | x |
| 2021-12-31 | Rp186.01 | Rp189.00 | x |
| 2022-12-31 | Rp203.23 | Rp189.00 | x |
| 2023-12-31 | Rp217.99 | Rp189.00 | x |
| 2024-12-31 | Rp221.75 | Rp189.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Millennium Pharmacon International utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.43%
- • Asset Turnover: 2.21x
- • Equity Multiplier: 6.27x
- Recent ROE (5.99%) is below the historical average (8.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 11.28% | 1.54% | 2.61x | 2.82x | Rp527.01 Million |
| 2004 | 8.57% | 0.92% | 3.08x | 3.03x | Rp-647.27 Million |
| 2005 | 13.46% | 1.46% | 2.99x | 3.09x | Rp1.81 Billion |
| 2006 | 13.89% | 1.38% | 3.48x | 2.89x | Rp2.36 Billion |
| 2007 | 13.68% | 1.36% | 3.04x | 3.30x | Rp2.59 Billion |
| 2008 | 11.94% | 1.09% | 2.84x | 3.87x | Rp1.54 Billion |
| 2009 | 10.66% | 0.94% | 3.77x | 3.00x | Rp585.37 Million |
| 2010 | 1.66% | 0.18% | 3.03x | 3.05x | Rp-7.57 Billion |
| 2011 | 4.22% | 0.41% | 3.01x | 3.41x | Rp-5.48 Billion |
| 2012 | 9.41% | 0.84% | 3.04x | 3.69x | Rp-614.26 Million |
| 2013 | 8.92% | 0.78% | 2.78x | 4.11x | Rp-1.24 Billion |
| 2014 | 6.01% | 0.51% | 2.71x | 4.35x | Rp-4.86 Billion |
| 2015 | 8.87% | 0.70% | 2.70x | 4.71x | Rp-1.52 Billion |
| 2016 | 7.75% | 0.56% | 2.69x | 5.12x | Rp-3.22 Billion |
| 2017 | 6.67% | 0.67% | 2.25x | 4.41x | Rp-7.08 Billion |
| 2018 | 8.38% | 0.82% | 1.99x | 5.14x | Rp-3.77 Billion |
| 2019 | 3.35% | 0.29% | 2.22x | 5.23x | Rp-15.66 Billion |
| 2020 | 1.22% | 0.11% | 2.27x | 5.08x | Rp-20.12 Billion |
| 2021 | 4.04% | 0.32% | 2.48x | 5.09x | Rp-14.13 Billion |
| 2022 | 9.45% | 0.76% | 2.28x | 5.41x | Rp-1.43 Billion |
| 2023 | 11.91% | 0.98% | 2.05x | 5.90x | Rp5.32 Billion |
| 2024 | 5.99% | 0.43% | 2.21x | 6.27x | Rp-11.34 Billion |
Industry Comparison
This section compares Millennium Pharmacon International's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $469,965,751,420
- Average return on equity (ROE) among peers: 54.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Millennium Pharmacon International (SDPC) | Rp300.33 Billion | 11.28% | 5.34x | $14.11 Million |
| Enseval Putra Megatrading Tbk (EPMT) | $576.81 Billion | 31.08% | 1.87x | $374.57 Million |
| Itama Ranoraya (IRRA) | $44.35 Billion | 54.06% | 1.88x | $34.10 Million |
| Kimia Farma Persero Tbk (KAEF) | $1.25 Trillion | 13.71% | 0.43x | $155.91 Million |
| Dosni Roha Indonesia Tbk PT (ZBRA) | $6.20 Billion | 117.13% | 11.72x | $117.43K |
About Millennium Pharmacon International
PT Millennium Pharmacon International Tbk engages in the distribution of prescription and non-prescription medicines and medical devices in Indonesia. The company was formerly known as PT NVPD Soedarpo Corporation Tbk and changed its name to PT Millennium Pharmacon International Tbk in February 1990. The company was founded in 1952 and is headquartered in Jakarta Selatan, Indonesia. PT Millennium… Read more